VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
HONG KONG and WENZHOU, China, June 10, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written...
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Jan. 8, 2025 /PRNewswire/ -- Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough results;...